ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2142

Magnetic Resonance Imaging-Proven Osteitis At Baseline Predicts the Early Rheumatoid Arthritis Patients Who Will Develop Rapid Radiographic Progression: MRI Is Beneficial to Find the Window of Opportunity in Early RA

Mami Tamai1, Yoshikazu Nakashima2, Takahisa Suzuki3, Yoshiro Horai2, Akitomo Okada4, Junko Kita4, Shin-ya Kawashiri2, Naoki Iwamoto4, Kunihiro Ichinose5, Kazuhiko Arima4, Hideki Nakamura1, Tomoki Origuchi6, Masataka Uetani7, Kiyoshi Aoyagi8, Katsumi Eguchi9 and Atsushi Kawakami2, 1Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 5Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 6Department of Health Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 7Department of Radiology and Radiation Research, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 8Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 9Sasebo City General Hospital, Sasebo, Nagasaki, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Bone marrow, Magnetic resonance imaging (MRI), radiography and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose: Window of opportunity exists in the earlier phase of rheumatoid arthritis (RA), thus, early recognition of the RA patients who will develop rapid radiographic progression (RRP) is crucial. We have reported an importance of magnetic resonance imaging (MRI)-proven symmetrical synovitis, osteitis and bone erosion of wrist and finger joints toward the early classification of RA from the prospective early arthritis cohort at Nagasaki University, Nagasaki, Japan. To investigate whether MRI assessment of joint injury at baseline predict the development of RRP at 2 years in patients with early RA by our cohort.

Methods: One hundred-eleven RA patients, who fulfilled 2010 RA classification criteria and introduced disease-modifying anti-rheumatic drugs (DMARDs) including biologics within the first 1 year, were consecutively enrolled in this study. These patients were referred to the RA patients in the present study. Patients gave their informed consent to be subjected to the protocol that was approved by the Institutional Review Board of Nagasaki University. All of the subjects had been examined by gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA)-enhanced MRI and plain radiograph of both wrist and finger joints at the same day every 6 months during 2 years. MRI-proven synovitis, osteitis and bone erosion were evaluated by RAMRI scoring (RAMRIS) technique. RRP was defined as yearly progression of Genant-modified Sharp score >3.0 during 2 years. We have examined what variables at entry, including MRI features, and the therapies during 2 years predict the development of RRP at 2 years by logistic regression analysis.

Results:

The mean disease duration, age, % female, prevalence or titer of rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA), disease activity score (DAS) 28-CRP at entry were 4.0 months, 56.2 y.o., 66.7%, 60.4% or 95.5 ± 186.7 IU/ml, 58.6% or 160.3 ± 345.4 U/ml and 4.38, respectively. The frequency of MRI-proven symmetrical synovitis, osteitis and bone erosion at baseline was 80.7, 54.5, 37.2%. Biologics were administrated in 17.1% of the patients during 2 years. Twenty patients (18.0%) were classified as RRP at 2 years. Logistic regression analysis has shown that MRI osteitis at baseline, history of biologics use during 2 years, Genant-modified Sharp score at baseline are independent variables to predict the development of RRP at 2 years (Odds ratio = 3.88, 7.95 and 12.4, respectively. 95% confidence interval = 1.05 – 14.42, 2.29 – 27.56 and 1.03-1.50, respectively, p-value = 0.043, 0.0011 and 0.027, respectively. Akaike’s information criterion = 91.50).

Conclusion:

Our present data indicate that MRI-proven osteitis at baseline is a predictor toward the development of RRP in patients with early RA. MRI is beneficial to find the window of opportunity in these patients.


Disclosure:

M. Tamai,
None;

Y. Nakashima,
None;

T. Suzuki,
None;

Y. Horai,
None;

A. Okada,
None;

J. Kita,
None;

S. Y. Kawashiri,
None;

N. Iwamoto,
None;

K. Ichinose,
None;

K. Arima,
None;

H. Nakamura,
None;

T. Origuchi,
None;

M. Uetani,
None;

K. Aoyagi,
None;

K. Eguchi,
None;

A. Kawakami,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/magnetic-resonance-imaging-proven-osteitis-at-baseline-predicts-the-early-rheumatoid-arthritis-patients-who-will-develop-rapid-radiographic-progression-mri-is-beneficial-to-find-the-window-of-opportu/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology